Alternations of Plasma Fatty Acids in Patients With Bipolar Depression Under Acute Treatment of rTMS Combined With Quetiapine and Mood Stabilizer

Huan Yu, Xue‐jun Liang, Yuting Qiao, Lin Guo, Ziyang Li, Cuihong Zhou, Wenjun Wu, Rui Li, Zhengwu PengBrain 2025 · DOI

TL;DR

This study investigates how plasma fatty acid (FA) profiles change in patients with bipolar depression undergoing a combination therapy of repetitive transcranial magnetic stimulation (rTMS), quetiapine, and mood stabilizers. The researchers identified specific FA panels that can effectively distinguish between patients with bipolar depression, healthy controls, and those after treatment, suggesting FAs could be potential biomarkers for diagnosis and treatment response.

What Problem Does This Paper Address?

Bipolar disorder (BD) is a severe mental health condition affecting millions worldwide, characterized by debilitating mood swings. Accurate diagnosis and effective treatment remain significant challenges, often taking years to achieve. While pharmacotherapy is the cornerstone of BD management, the role of adjunctive treatments like rTMS is gaining attention. However, the underlying biological mechanisms, particularly how these treatments affect metabolic pathways, are not well understood. Specifically, the impact of rTMS combined with standard pharmacotherapy on the body's fatty acid composition in individuals with bipolar depression has not been previously explored. This paper aims to fill this knowledge gap by examining plasma FA profiles before and after a 2-week course of this combined treatment, seeking to uncover potential diagnostic biomarkers and understand the metabolic underpinnings of treatment response.

Methods

The study employed a comparative design involving three groups: 30 inpatients with bipolar depression (BD group), the same 30 patients after 2 weeks of treatment with rTMS combined with quetiapine and mood stabilizer (BD-2w group), and 32 healthy controls (HCs).

Key techniques and approaches:

  • Clinical Assessment: Standardized scales like the Bech-Rafaelsen Mania Rating Scale (BRMS), 17-item Hamilton Depression Rating Scale (HAMD), and Hamilton Anxiety Scale (HAMA) were used to assess symptom severity.
  • Plasma Fatty Acid Analysis:
    • Short-Chain Fatty Acids (SCFAs): Measured using liquid chromatography-mass spectrometry (LC/MS).
  • Medium- and Long-Chain Fatty Acids (MLCFAs): Measured using gas chromatography-mass spectrometry (GC-MS).
  • Statistical Analysis:
    • Shapiro-Wilk test for normality.
  • Independent or paired samples t-tests for normally distributed data.
  • Wilcoxon test or Mann-Whitney U test for abnormally distributed data.
  • MetaboAnalyst 5.0 was used for random forest analysis and receiver operating characteristic (ROC) curve generation to identify potential biomarker panels.
  • Spearman correlation analysis was used to assess correlations between FA levels and clinical parameters.

Datasets

The study utilized plasma samples collected from:

  • 30 inpatients diagnosed with bipolar depression.
  • 32 healthy controls.
  • The same 30 bipolar depression patients after 2 weeks of combined rTMS and pharmacotherapy.

No new benchmark datasets were introduced; the study focused on analyzing existing biological samples from distinct patient and control groups.

Key Insights and Ideas

  • Distinct FA Signatures: Bipolar depression is associated with significant alterations in plasma FA profiles compared to healthy individuals, with specific SCFAs and MLCFAs showing decreased levels in patients.
  • Treatment-Induced Normalization: The combined rTMS and pharmacotherapy intervention led to a partial normalization of some FA levels, particularly an increase in omega-3 polyunsaturated fatty acids (N3 PUFAs), suggesting a positive metabolic impact.
  • Diagnostic Potential of FAs: The study successfully developed FA panels that can effectively differentiate between BD patients and HCs, treated BD patients and HCs, and even between BD patients before and after treatment. This highlights the potential of FAs as objective biomarkers for diagnosis and treatment monitoring.
  • Correlation with Clinical Markers: Certain FA levels showed significant correlations with clinical symptom scores (HAMA, HAMD, BRMS) and metabolic markers (LDL, BMI, TG, CHOL), further underscoring their relevance to the disease state and treatment response.

Key Results

  • SCFAs: Total SCFAs, acetic acid, propionic acid, isovaleric acid, isobutyric acid, and valeric acid were significantly decreased in both the BD and BD-2w groups compared to HCs. Notably, after 2 weeks of treatment, levels of butyric acid and caproic acid increased, with caproic acid showing a significant increase in BD-2w compared to BD.
  • MLCFAs (PUFAs): While some PUFAs showed alterations in BD patients compared to HCs (e.g., increased C22:4, C22:5n6; decreased C18:2n6c), the BD-2w group showed increased levels of several MLCFAs, including total PUFAs and N3 PUFAs, compared to both BD and HC groups.
  • Biomarker Panels:
    • A panel of FAs could distinguish BD from HC with an AUC of 0.961.
  • A different panel could distinguish BD-2w from HC with an AUC of 0.978.
  • A third panel could distinguish BD from BD-2w with an AUC of 0.891.
  • Clinical Data: Significant differences were observed in symptom scores (HAMA, HAMD) and lipid profiles (LDL, TG, CHOL) between BD and HC groups. Treatment with rTMS and pharmacotherapy led to a significant decrease in HAMA, HAMD, and BRMS scores, indicating symptom improvement.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small Sample Size: The study was conducted with a relatively small number of participants, limiting generalizability.
  • No Distinction Between Bipolar I and II: The study did not differentiate between bipolar I and bipolar II disorder, which may have distinct FA profiles.
  • Lack of Validation Cohort: The identified FA panels were not validated in an independent cohort.
  • Variability in Pharmacotherapy: Patients received different types of mood stabilizers, and the daily dosage of quetiapine was not strictly controlled, introducing variability.
  • No Monotherapy Control Group: The study combined rTMS with pharmacotherapy, making it difficult to ascertain the specific contribution of each component or potential synergistic effects.
  • Dietary and Previous Treatment Influence: The study did not strictly control for dietary intake during hospitalization, nor did it account for the influence of previous treatments or medications.
  • Causality: The causal relationship between FA changes and BD symptoms remains unclear.

Future work suggested by the authors:

  • Conducting larger-scale studies with distinct bipolar I and II subgroups.
  • Establishing validation cohorts for the identified FA biomarker panels.
  • Investigating the specific contributions of rTMS and different pharmacotherapies through monotherapy control groups.
  • Exploring the impact of dietary interventions and controlling for previous medication history.
  • Further research into the causal mechanisms linking FA alterations to BD pathophysiology and treatment response, including the role of gut microbiota and exogenous MLCFA supplementation.

Summary updated

Abstract

These findings might provide a basis for developing diagnostic methods and reveal the potential relationship between bipolar depression and plasma FAs.
BibTeX
@inproceedings{yu2025alternations,
  author = {Huan Yu and Xue‐jun Liang and Yuting Qiao and Lin Guo and Ziyang Li and Cuihong Zhou and Wenjun Wu and Rui Li and Zhengwu Peng},
  title = {{Alternations of Plasma Fatty Acids in Patients With Bipolar Depression Under Acute Treatment of rTMS Combined With Quetiapine and Mood Stabilizer}},
  booktitle = {Brain},
  year = {2025},
  doi = {10.1002/brb3.70341},
}
Figure